Mifepristone FDA Link

A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME.

Also Known As:

RU 486; Mifeprex; RU-486; RU486; Mifegyne; Mifégyne; R-38486; R38486; RU-38486; ZK-98296; ZK98296; R 38486; RU 38486; RU38486; ZK 98296; Estra-4,9-dien-3-one, 11- (4- (dimethylamino)phenyl)- 17- hydroxy- 17- (1- propynyl)- , (11beta,17beta)-

Pharmalogical Action Categories:

Abortifacient Agents, Steroidal
Contraceptives, Oral, Synthetic
Contraceptives, Postcoital, Synthetic
Hormone Antagonists
Luteolytic Agents
Menstruation-Inducing Agents

Polycyclic Compounds: 6
- Fused-Ring Compounds
  - Steroids: 70059
    - Estranes
      - Estrenes
        Mifepristone: 1726

Barbara Rodriguez Selected Research

Barbara Rodriguez Research Topics

Disease

Drug/Important Bio-Agent (IBA)